{"nctId":"NCT02797132","briefTitle":"Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Through 5 Years With Cystic Fibrosis, Homozygous for F508del","startDateStruct":{"date":"2016-05","type":"ACTUAL"},"conditions":["Cystic Fibrosis"],"count":62,"armGroups":[{"label":"Lumacaftor/Ivacaftor (LUM/IVA)","type":"EXPERIMENTAL","interventionNames":["Drug: LUM/IVA"]}],"interventions":[{"name":"LUM/IVA","otherNames":["Orkambi","VX-809+VX-770"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subjects who weigh â‰¥8 kilogram (kg) without shoes and wearing light clothing at the Screening Visit\n* Subjects with confirmed diagnosis of CF at the Screening Visit\n* Subjects who are homozygous for the F508del-cystic fibrosis transmembrane conductance regulator (CFTR) mutation\n\nExclusion Criteria:\n\n* Any clinically significant laboratory abnormalities at the Screening Visit that would interfere with the study assessments or pose an undue risk for the subject\n* An acute upper or lower respiratory infection, pulmonary exacerbation, or changes in therapy (including antibiotics) for pulmonary disease within 28 days before Day 1\n* A standard 12-lead ECG demonstrating QTc \\>450 millisecond (msec) at the Screening Visit.\n* History of solid organ or hematological transplantation.\n* Ongoing or prior participation in an investigational drug study (including studies investigating LUM and/or IVA) within 30 days of the Screening Visit.\n* History of cataract/lens opacity or evidence of cataract/lens opacity determined to be clinically significant by a licensed ophthalmologist during the ophthalmologic examination at the Screening Visit","healthyVolunteers":false,"sex":"ALL","minimumAge":"2 Years","maximumAge":"5 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Part A: Pre-dose Concentration (Ctrough) of LUM and IVA","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8710","spread":"3590"},{"groupId":"OG001","value":"12300","spread":"5960"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.0","spread":"67.0"},{"groupId":"OG001","value":"216","spread":"185"}]}]}]},{"type":"PRIMARY","title":"Part B: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"40","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Part A: Pre-dose Concentration (Ctrough) of LUM and IVA Metabolites","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1310","spread":"590"},{"groupId":"OG001","value":"1370","spread":"286"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"475","spread":"384"},{"groupId":"OG001","value":"1240","spread":"1180"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1510","spread":"1130"},{"groupId":"OG001","value":"3270","spread":"2100"}]}]}]},{"type":"SECONDARY","title":"Part A: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Part B: Absolute Change From Baseline in Sweat Chloride at Week 24","description":"Sweat samples were collected using an approved collection device.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-33.5","spread":"14.5"},{"groupId":"OG001","value":"-30.7","spread":"14.0"}]}]}]},{"type":"SECONDARY","title":"Part B: Absolute Change From Baseline in Body Mass Index (BMI) at Week 24","description":"BMI was defined as weight in kilograms (kg) divided by height in square meter (m\\^2).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.22","spread":"0.78"},{"groupId":"OG001","value":"0.29","spread":"0.75"}]}]}]},{"type":"SECONDARY","title":"Part B: Absolute Change From Baseline in Body Mass Index (BMI) For-Age Z-Score at Week 24","description":"BMI was defined as weight in kg divided by height in m\\^2. z-score is a statistical measure to describe whether a mean was above or below the standard. BMI, adjusted for age and sex, was analyzed as BMI-for-age z-score (BMI z-score).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.36","spread":"0.67"},{"groupId":"OG001","value":"0.26","spread":"0.53"}]}]}]},{"type":"SECONDARY","title":"Part B: Absolute Change From Baseline in Weight at Week 24","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":"0.7"},{"groupId":"OG001","value":"1.5","spread":"1.0"}]}]}]},{"type":"SECONDARY","title":"Part B: Absolute Change From Baseline in Weight-for-age Z-Score at Week 24","description":"z-score is a statistical measure to describe whether a mean was above or below the standard. Weight, adjusted for age and sex, was analyzed as weight-for-age z-score (Weight z-score).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.44","spread":"0.52"},{"groupId":"OG001","value":"0.17","spread":"0.36"}]}]}]},{"type":"SECONDARY","title":"Part B: Absolute Change From Baseline in Stature (Height) at Week 24","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.1","spread":"1.4"},{"groupId":"OG001","value":"3.4","spread":"1.0"}]}]}]},{"type":"SECONDARY","title":"Part B: Absolute Change From Baseline in Stature-for-Age Z-Score","description":"z-score is a statistical measure to describe whether a mean was above or below the standard. Stature (height), adjusted for age and sex, was analyzed as Stature-for-age z-score (Stature z-score).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.19","spread":"0.32"},{"groupId":"OG001","value":"0.04","spread":"0.19"}]}]}]},{"type":"SECONDARY","title":"Part B: Number of Pulmonary Exacerbations","description":"Pulmonary exacerbation was defined as new or changed treatment with oral, inhaled, or intravenous antibiotics and fulfillment of pre-specified protocol defined criteria.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"20","spread":null}]}]}]},{"type":"SECONDARY","title":"Part B: Number of Participants With at Least One Pulmonary Exacerbation Pulmonary Exacerbation Through Week 24","description":"Pulmonary exacerbation was defined as new or changed treatment with oral, inhaled, or intravenous antibiotics and fulfillment of pre-specified protocol defined criteria. Time to event data was not collected and instead, number of participants with first event were collected and are reported. Time-to-first pulmonary exacerbation was planned to be estimated using Kaplan-Meier (KM) estimates. However, due to less than 50% of events, time-to-first event data was not estimated. Instead, number of participants with at least one pulmonary exacerbation event were collected and are reported.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]}]},{"type":"SECONDARY","title":"Part B: Number of Cystic Fibrosis (CF)-Related Hospitalizations","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Part B: Absolute Change From Baseline in Fecal Elastase-1 (FE-1) Levels at Week 24","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"38.4","spread":"76.1"},{"groupId":"OG001","value":"60.0","spread":"94.0"}]}]}]},{"type":"SECONDARY","title":"Part B: Absolute Change From Baseline in Serum Levels of Immunoreactive Trypsinogen (IRT) Through Week 24","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-262.1","spread":"343.1"},{"groupId":"OG001","value":"-71.1","spread":"120.5"}]}]}]},{"type":"SECONDARY","title":"Part B: Number of Participants With Microbiology Culture Status (Positive or Negative) at Week 24","description":"Following microbial tests were performed: Burkholderia, Methicillin Resistant Staphylococcus Aureus (MRSA), Methicillin Susceptible Staphylococcus Aureus (MSSA), Pseudomonas Aeruginosa Mucoid (P. Aeruginosa Mucoid), P. Aeruginosa Non-Mucoid, P. Aeruginosa Small Colony Variant and Stenotrophomonas Maltophilia.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"37","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"36","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"33","spread":null}]},{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"35","spread":null}]},{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"26","spread":null}]},{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"12","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"26","spread":null}]},{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"37","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"35","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"35","spread":null}]},{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"34","spread":null}]},{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"38","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19","spread":null},{"groupId":"OG001","value":"36","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"37","spread":null}]},{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"36","spread":null}]},{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Part B: Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1) at Week 24","description":"FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.","classes":[{"categories":[{"measurements":[{"groupId":"OG001","value":"0.5","spread":"11.6"}]}]}]},{"type":"SECONDARY","title":"Part B: Absolute Change in Sweat Chloride From Week 24 at Week 26","description":"Sweat samples were collected using an approved collection device.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.4","spread":"14.9"},{"groupId":"OG001","value":"32.2","spread":"13.8"}]}]}]},{"type":"SECONDARY","title":"Part B: Acceptability/Palatability of LUM/IVA Granules Measured Using Hedonic Scale","description":"The acceptability and palatability of LUM/IVA granules was assessed by a visual analog scale that incorporates a 5 point facial hedonic scale (Liked it Very Much, Liked it a Little, Not sure, Disliked it a Little, Disliked it Very Much). The assessment was conducted in 2 steps: assessment of approved food/liquid (Evaluation 1), and assessment of approved food/liquid with LUM/IVA granules (Evaluation 2).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"30","spread":null}]},{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"6","spread":null}]},{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"1","spread":null}]},{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]},{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"6","spread":null}]},{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"5","spread":null}]},{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"6","spread":null}]},{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"6","spread":null}]},{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"15","spread":null}]}]}]},{"type":"SECONDARY","title":"Part B: Absolute Change From Baseline in Lung Clearance Index (LCI) 2.5 at Week 24","description":"Lung clearance index (LCI) is a measure of ventilation inhomogeneity that is derived from a multiple breath washout test using Nitrogen (N2). LCI 2.5 represents the number of lung turnovers required to reduce the end tidal inert gas concentration to 1/40th of its starting value.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.27","spread":"0.48"},{"groupId":"OG001","value":"-0.76","spread":"1.19"}]}]}]},{"type":"SECONDARY","title":"Part B: Absolute Change From Baseline in Lung Clearance Index (LCI) 5.0 at Week 24","description":"LCI is a measure of ventilation inhomogeneity that is derived from a multiple breath washout test using Nitrogen (N2). LCI 5.0 represents the number of lung turnovers required to reduce the end tidal inert gas concentration to 1/20th of its starting value.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.24","spread":"0.40"},{"groupId":"OG001","value":"-0.12","spread":"0.69"}]}]}]},{"type":"SECONDARY","title":"Part B: Pre-dose Concentration (Ctrough) of LUM and IVA and Its Metabolites","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9060","spread":"4060"},{"groupId":"OG001","value":"9390","spread":"4830"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1420","spread":"846"},{"groupId":"OG001","value":"1510","spread":"752"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"108","spread":"109"},{"groupId":"OG001","value":"110","spread":"108"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"555","spread":"560"},{"groupId":"OG001","value":"521","spread":"478"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2050","spread":"1940"},{"groupId":"OG001","value":"1900","spread":"1430"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":4},"commonTop":["Cough","Vomiting","Pyrexia","Rhinorrhoea","Nasal congestion"]}}}